Impact of the conversion of the immunosuppressive regimen from Prograf to Advagraf or to Sirolimus in long-term stable liver transplant recipients: Indications, safety, and outcome

Transplantation Proceedings

Volumn 43, Issue 10, 2011, Pages 3702-3707

  Perrakis, A ^a   Schwarz, K ^a   Yedibela, S ^a   Croner, R S ^a   Hohenberger, W ^a   Mller, V ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; DACLIZUMAB; ERYTHROPOIETIN; GENTAMICIN; METHYLPREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ACUTE LIVER FAILURE; ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ANKLE EDEMA; APHTHOUS STOMATITIS; AUTOIMMUNE CIRRHOSIS; BUDD CHIARI SYNDROME; CHOLESTATIC LIVER DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYPTOGENIC CIRRHOSIS; DATA BASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; TACHYCARDIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; GERMANY; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; SIROLIMUS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 83655211672     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.09.015     Document Type: Conference Paper

References (30)

1. Y. Calmus Immunosuppression after liver transplantation Press Med 38 2009 1307
2. N. Weiler, I. Thrun, M. Hoppe-Lotichius Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial Transplantation 90 2010 1562
3. J.P. van Hooff, R.R. Alloway, P. Trunecka Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies Clin Transplant 25 2011 E1
4. L.M. Marin-Gomez, M.A. Gomez-Bravo, J.A. Alamo-Martinez Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study Transplant Proc 41 2009 2184
5. M.R. First First clinical experience with the new once-daily formulation of tacrolimus Ther Drug Monit 30 2008 159
6. I.M. Subbiah, R.E. Brown, M.B. Fallon Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma Hepatology 52 2010 1524
7. A.A. Schnitzbauer, C. Zuelke, C. Graeb A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma BMC Cancer 10 2010 190
8. S. Bhoori, S. Toffanin, C. Sposito Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle J Hepatol 52 2010 771
9. S.K. Asrani, M.D. Leise, C.P. West Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis Hepatology 52 2010 1360
10. A. Barkmann, B. Nashan, H.H. Schmidt Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil Transplantation 69 2000 1886
11. I. Morard, G. Mentha, L. Spahr Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels Clin Transplant 20 2006 96
12. Y.J. Yang, D.Z. Chen, L.X. Li Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency Transplant Proc 40 2008 1541
13. T.A. Gonwa, M.L. Mai, L.B. Melton End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment Transplantation 72 2001 1934
14. E.A. Burdmann, T.F. Andoh, L. Yu Cyclosporine nephrotoxicity Semin Nephrol 23 2003 465
15. K.D. Fairbanks, P.J. Thuluvath Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience Liver Transpl 10 2004 1189
16. J.M. Moreno, E. Rubio, A. Gómez Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation Transplant Proc 35 2003 1874
17. A. Pierini, S. Mirabella, A. Brunati Mycophenolate mofetil monotherapy in liver transplantation Transplant Proc 37 2005 2614
18. J.M. Hougardy, N. Broeders, M. Kianda Conversion from prograf to advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure Transplantation 91 2011 566
19. P. Trunecka, O. Boillot, D. Seehofer Tacrolimus Prolonged Release Liver Study Group Oncedaily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation Am J Transplant 10 2010 2313
20. C. Comuzzi, D. Lorenzin, A. Rossetto Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients Transplant Pro 42 2010 1320
21. J.B. Woillard, B.C. de Winter, N. Kamar Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations - twice daily Prograf (®) and once daily Advagraf(®) J Clin Pharmacol 71 2011 391
22. K.D. Fairbanks, J.A. Eustace, D. Fine Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus Liver Transpl 9 2003 1079
23. L. Bckman, A.V. Reisaeter, L. Wramner Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus Clin TransPlant 20 2006 336
24. M. Vivarelli, A. Dazzi, A. Cucchetti Sirolimus in liver transplant recipients: a large single-center experience Transplant Proc 42 2010 2579
25. F. Di Benedetto, S. Di Sandro, N. De Ruvo Sirolimus monotherapy in liver transplantation Transplant Proc 39 2007 193
26. F. Di Benedetto, S. Di Sandro, N. De Ruvo Kaposi's sarcoma after liver transplantation J Cancer Res Clin Oncol 134 2008 653
27. C.C. Rogers, S.R. Johnson, D.A. Mandelbrot Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients Clin Transplant 23 2009 887
28. G.W. Neff, P. Ruiz, J.R. Madariaga Sirolimus-associated hepatotoxicity in liver transplantation Ann Pharmacother 38 2004 1593
29. M. Niemczyk, J. Wyzgal, A. Perkowska Sirolimus-associated hepatotoxicity in the kidney graft recipient Transpl Int 18 2005 1302
30. C.J. Watson, A.E. Gimson, G.J. Alexander A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function Liver Transpl 13 2007 1694